Efficacy gap between phase II and subsequent phase III studies in oncology

AIMS: There is a trend for more flexibility in timing of evidence generation in relation to marketing authorization, including the option to complete phase III trials after authorization or not at all. This paper investigated the relation between phase II and III clinical trial efficacy in oncology....

Descripción completa

Detalles Bibliográficos
Autores principales: Vreman, Rick A., Belitser, Svetlana V., Mota, Ana T.M., Hövels, Anke M., Goettsch, Wim G., Roes, Kit C.B., Leufkens, Hubert G.M., Mantel‐Teeuwisse, Aukje K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7318994/
https://www.ncbi.nlm.nih.gov/pubmed/32034790
http://dx.doi.org/10.1111/bcp.14237

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7318994/
https://www.ncbi.nlm.nih.gov/pubmed/32034790
http://dx.doi.org/10.1111/bcp.14237

Ejemplares similares